Discover the latest insights & resources from ROIS below
Articles
Water for Injection: Why WFI Is Now a Strategic Manufacturing Decision
As biologics, vaccines, and high-value injectables drive demand, WFI has become a strategic constraint, with regulatory, cost, and operational implications that can delay or derail programs.
Explore why WFI is no longer an afterthought, when outsourcing makes sense, and what to consider when choosing a CDMO partner.
ROIS Reflects on 2025: Innovation, Investment and Global Growth
From major investments to global expansion, 2025 marked a defining year in ROIS’s continued evolution as a leading injectable CDMO.
CDMO Partnerships: Why Speed and Flexibility Matter Now More Than Ever
What used to be acceptable in 18 months, clients now want in 9 – with particular urgency for GLP-1s and biologics.
Scaling for the GLP-1 Revolution - Meeting Global Injectable Demand
It’s not just about being fast. It’s about being reliable and ready.
